Cargando…

Urinary glucose excretion after dapagliflozin treatment: An exposure‐response modelling comparison between Japanese and non‐Japanese patients diagnosed with type 1 diabetes mellitus

AIMS: To assess the dapagliflozin exposure‐response relationship in Japanese and non‐Japanese patients with type 1 diabetes mellitus (T1DM) and investigate if a dose adjustment is required in Japanese patients. MATERIALS AND METHODS: Data from two clinical studies were used to develop a non‐linear m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sokolov, Victor, Yakovleva, Tatiana, Ueda, Shinya, Parkinson, Joanna, Boulton, David W., Penland, Robert C., Tang, Weifeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590404/ https://www.ncbi.nlm.nih.gov/pubmed/30456904 http://dx.doi.org/10.1111/dom.13586

Ejemplares similares

Effectiveness of dapagliflozin as an insulin adjunct in type 1 diabetes: a semi-mechanistic exposure-response model
por: Sokolov, Victor, et al.
Publicado: (2023)

Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling
por: Sokolov, Victor, et al.
Publicado: (2020)

Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus
por: Melin, Johanna, et al.
Publicado: (2022)

A mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetes
por: Sokolov, Victor, et al.
Publicado: (2023)

Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes
por: Watada, Hirotaka, et al.
Publicado: (2018)

Impact of Voglibose on the Pharmacokinetics of Dapagliflozin in Japanese Patients with Type 2 Diabetes
por: Imamura, Akira, et al.
Publicado: (2013)

Model‐Informed Pediatric Dose Selection for Dapagliflozin by Incorporating Developmental Changes
por: Jo, Heeseung, et al.
Publicado: (2021)

Model‐based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus
por: Parkinson, Joanna, et al.
Publicado: (2019)

Effect of Canagliflozin on Urinary Albumin Excretion in Japanese Patients with Type 2 Diabetes Mellitus and Microalbuminuria: A Pilot Study
por: Osonoi, Takeshi, et al.
Publicado: (2018)

Clinical and genetic determinants of urinary glucose excretion in patients with diabetes mellitus
por: Monobe, Keisuke, et al.
Publicado: (2020)

Association of BAP with urinary albumin excretion in postmenopausal, but not premenopausal, non-CKD Japanese women
por: Ozaki, Etsuko, et al.
Publicado: (2018)

Association of Serum Carotenoid Levels With Urinary Albumin Excretion in a General Japanese Population: The Yakumo Study
Publicado: (2013)

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus
por: Whaley, Jean M, et al.
Publicado: (2012)

Associations of Plasma Concentration Profiles of Dapagliflozin, a Selective Inhibitor of Sodium–Glucose Co-Transporter Type 2, with Its Effects in Japanese Patients with Type 2 Diabetes Mellitus
por: Hayakawa, Tetsuo, et al.
Publicado: (2022)

Common UGT1A9 polymorphisms do not have a clinically meaningful impact on the apparent oral clearance of dapagliflozin in type 2 diabetes mellitus
por: Naagaard, M. Daniel, et al.
Publicado: (2022)

Association between urinary zinc excretion and isoflavone-metabolizing enterotypes among Japanese females: a cross-sectional study
por: Fujitani, Tomoko, et al.
Publicado: (2023)

Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study)
por: Kinguchi, Sho, et al.
Publicado: (2019)

K(+) Excretion: The Other Purpose for Puddling Behavior in Japanese Papilio Butterflies
por: Inoue, Takashi A., et al.
Publicado: (2015)

Quantitative Systems Pharmacology: An Exemplar Model‐Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development
por: Helmlinger, Gabriel, et al.
Publicado: (2019)

Dapagliflozin as Monotherapy or Combination Therapy in Japanese Patients with Type 2 Diabetes: an Open-Label Study
por: Kaku, Kohei, et al.
Publicado: (2014)

Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
por: Li, Feng-fei, et al.
Publicado: (2016)

Placing Salt/Soy Sauce at Dining Tables and Out-Of-Home Behavior Are Related to Urinary Sodium Excretion in Japanese Secondary School Students
por: Okuda, Masayuki, et al.
Publicado: (2017)

Factors associated with the glucose‐lowering efficacy of sitagliptin in Japanese patients with type 2 diabetes mellitus: Pooled analysis of Japanese clinical trials
por: Tajima, Naoko, et al.
Publicado: (2019)

The effect of dapagliflozin on uric acid excretion and serum uric acid level in advanced CKD
por: Iwata, Yukimasa, et al.
Publicado: (2023)

Urinary BK Virus Excretion in Children Newly Diagnosed with Acute Lymphoblastic Leukemia
por: Raeesi, Nahid, et al.
Publicado: (2012)

Estimation of daily sodium and potassium excretion from overnight urine of Japanese children and adolescents
por: Okuda, Masayuki, et al.
Publicado: (2020)

Concentrations of Water-Soluble Vitamins in Blood and Urinary Excretion in Patients with Diabetes Mellitus
por: Iwakawa, Hiromi, et al.
Publicado: (2016)

Dietary intake habits and the prevalence of nocturia in Japanese patients with type 2 diabetes mellitus
por: Furukawa, Shinya, et al.
Publicado: (2017)

A Nonlinear Mixed Effects Pharmacokinetic Model for Dapagliflozin and Dapagliflozin 3-O-glucuronide in Renal or Hepatic Impairment
por: van der Walt, J-S, et al.
Publicado: (2013)

Interaction Between the Sodium‐Glucose–Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects
por: Wilcox, Christopher S., et al.
Publicado: (2018)

Sustained Decrease of Early-Phase Insulin Secretion in Japanese Women with Gestational Diabetes Mellitus Who Developed Impaired Glucose Tolerance and Impaired Fasting Glucose Postpartum
por: Katayama, Hiroko, et al.
Publicado: (2015)

Predictors of Incident Type 2 Diabetes Mellitus in Japanese Americans with Normal Fasting Glucose Level
por: Hwang, You-Cheol, et al.
Publicado: (2018)

Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
por: Fioretto, Paola, et al.
Publicado: (2015)

FRI649 ADMIRE: Assessing Dapagliflozin And Metformin As An Initial Regimen In Diabetes Mellitus For Enhanced Glucose Control
por: Phadke, Dr Uday, et al.
Publicado: (2023)

Urinary pseudouridine excretion in myelomatosis.
por: Sørensen, S. H., et al.
Publicado: (1985)

Iodine Excretion in 24-hour Urine Collection and Its Dietary Determinants in Healthy Japanese Adults
por: Katagiri, Ryoko, et al.
Publicado: (2016)

Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2013)

Nocturia and prevalence of erectile dysfunction in Japanese patients with type 2 diabetes mellitus: The Dogo Study
por: Furukawa, Shinya, et al.
Publicado: (2016)

The impact of hyperglycemia on urinary albumin excretion in recent onset diabetes mellitus type II
por: Nikolaidou, Barbara, et al.
Publicado: (2020)

Changes in urinary potassium excretion in patients with chronic kidney disease
por: Ueda, Yuichiro, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_8vpqgpm51tuspcgq07nm5r3auu